Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags B-cell non-Hodgkin Lymphoma

Tag: B-cell non-Hodgkin Lymphoma

ASH 2020: Positive Interim Phase I Study Results of TRPH-222 in...

Peter Hofland
TRPH-222 (CD22-4AP), an antibody-drug conjugate (ADC) being developed by Triphase, demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients...

European Commission Approves Brentuximab Vedotin for Consolidation Treatment in Post-Transplant Hodgkin...

Peter Hofland
The European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology) and approved the drug for the treatment of...

First Patient Dosed in Phase I Trial of ADCT-402 in CD-19...

ADC Review | Editorial Team
Late last week, Swiss based ADC Therapeutics, an oncology drug development company that specializes in the development of proprietary antibody-drug conjugates (ADCs) targeting major...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X